2021 American Transplant Congress
Conversion to Belatacept Based Immunosuppression Regimen in Kidney Transplant Patients: Lessons Learned
*Purpose: The costimulatory inhibitor, belatacept (Bela) has been shown to be an effective alternative in several clinical situations including calcineurin toxicity, de novo alloantibody formation…2021 American Transplant Congress
Degree of T Cell Infiltration Predicts Treatment Response in Pediatric Liver Late Acute Cellular Rejection
Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: Late acute cellular rejection (ACR) occurs >6mo post-liver transplant and is associated with chronic rejection and allograft loss. Currently, no diagnostic features predict ACR…2021 American Transplant Congress
A Comparison of Pediatric Intestine Transplant Between the Current Era (2015-2019) and the Peak Period (2002-2006)
1Seattle Children's Hospital, Seattle, WA, 2SRTR, Minneapolis, MN
*Purpose: Demand for intestine transplants in children grew from its clinical inception in the late 1980s to a peak in 2007 of 111 small bowel-containing…2021 American Transplant Congress
T-Cell Exhaustion in EBV DNAemic Solid Organ Transplant Recipients
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada
*Purpose: In transplant recipients, disease severity after infection with Epstein-Barr virus (EBV) may range from asymptomatic DNAemia to PTLD. Host factors likely play a key…2021 American Transplant Congress
Racial and Sexual Disparities in Solid Organ Transplant Outcomes Since Implementation of the Affordable Care Act Insurance Expansion Across Some States
*Purpose: Achieving solid organ transplantation traditionally requires access to health insurance. As such, women and people of color have faced barriers to obtaining solid-organ transplants.…2021 American Transplant Congress
Evolving Trends in Risk Profiles and Outcomes in Older Adults Undergoing Kidney Re-Transplantation
1McGill University, Montreal, QC, Canada, 2Johns Hopkins University, Baltimore, MD
*Purpose: The half-life of a kidney transplant (KT) is 8-12 years, and a significant proportion of patients end up with graft loss at age ≥65…2021 American Transplant Congress
AT-1501, a Novel and Clinically Applicable CD40L Specific Monoclonal Antibody, Promotes Islet Allograft Survival in Nonhuman Primates
*Purpose: Immune intervention with a CD40L specific monoclonal antibody (mAb, Hu5c8, Biogen) has previously been shown to safely and effectively prevent islet allograft (IA) rejection…2021 American Transplant Congress
Outcomes of Short-Duration Anti-Viral Prophylaxis for Hepatitis C Positive Donor Kidney Transplants
Virginia Commonwealth University Health System, Richmond, VA
*Purpose: Trials describing 4-12 week courses of direct-acting anti-viral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant…2021 American Transplant Congress
Pilot Study for the Use of Shortened Preemptive Therapy with Glecaprevir/pibrentasvir (g/p) and Ezetimibe in Hepatitis C Seronegative Solid Organ Transplant Recipients (Kidney and Heart) of Hepatitis C Viremic Donors
*Purpose: This prospective study aims to assess the efficacy of preemptive therapy with eight days of a combination of direct-acting antivirals (DAAs) (Mavyret) (Pibrentasvir /Glecaprevir)…
American Transplant Congress abstracts